Want to see HK:6978 full AI Analyst Report?
Immunotech Biopharm Ltd (6978) Ratios
Immunotech Biopharm Ltd Ratios
HK:6978's free cash flow for Q2 2026 was $-75.43M. For the 2026 fiscal year, HK:6978's free cash flow was decreased by $-10.22M and operating cash flow was $-65.21M. See a summary of the company’s cash flow.
| Ratios | Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 |
|---|---|---|---|---|---|
| Liquidity Ratios | |||||
| Current Ratio | 0.35 | 0.20 | 1.05 | 0.57 | 2.29 |
| Quick Ratio | 0.34 | 0.19 | 1.03 | 0.53 | 2.23 |
| Cash Ratio | 0.11 | 0.11 | 0.26 | 0.28 | 1.96 |
| Solvency Ratio | -0.31 | -0.23 | -0.42 | -0.74 | -1.21 |
| Operating Cash Flow Ratio | -0.20 | -0.29 | -0.80 | -0.87 | -1.41 |
| Short-Term Operating Cash Flow Coverage | -0.29 | -0.47 | -0.50 | 0.00 | 0.00 |
| Net Current Asset Value | $ -397.51M | $ -493.00M | $ -461.50M | $ -254.95M | $ 137.69M |
| Leverage Ratios | |||||
| Debt-to-Assets Ratio | 0.73 | 0.68 | 0.93 | 0.17 | 0.10 |
| Debt-to-Equity Ratio | -31.60 | -28.92 | 4.52 | 0.29 | 0.14 |
| Debt-to-Capital Ratio | 1.03 | 1.04 | 0.82 | 0.23 | 0.12 |
| Long-Term Debt-to-Capital Ratio | 0.00 | 0.00 | 0.65 | 0.00 | 0.00 |
| Financial Leverage Ratio | -43.29 | -42.42 | 4.87 | 1.73 | 1.33 |
| Debt Service Coverage Ratio | -0.49 | -0.54 | -0.55 | -42.84 | -93.86 |
| Interest Coverage Ratio | -23.50 | -30.95 | 0.00 | -44.65 | -93.76 |
| Debt to Market Cap | 0.23 | 0.24 | 0.30 | 0.00 | 0.00 |
| Interest Debt Per Share | 0.81 | 0.76 | 1.52 | 0.30 | 0.22 |
| Net Debt to EBITDA | -2.29 | -2.27 | -4.09 | -0.40 | 0.75 |
| Profitability Margins | |||||
| Gross Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBIT Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EBITDA Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Pretax Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Continuous Operations Profit Margin | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Net Income Per EBT | 99.95% | 100.27% | 99.80% | 99.07% | 99.89% |
| EBT Per EBIT | 148.21% | 93.78% | 145.51% | 117.22% | 102.83% |
| Return on Assets (ROA) | -38.26% | -33.14% | -39.56% | -36.17% | -32.27% |
| Return on Equity (ROE) | 1656.40% | 1405.78% | -192.85% | -62.57% | -43.08% |
| Return on Capital Employed (ROCE) | -138.94% | -148.53% | -35.86% | -40.83% | -37.58% |
| Return on Invested Capital (ROIC) | -32.83% | -46.29% | -23.19% | -39.30% | -36.77% |
| Return on Tangible Assets | -39.43% | -34.33% | -41.62% | -38.01% | -32.69% |
| Earnings Yield | -15.97% | -16.81% | -15.61% | -15.12% | -5.02% |
| Efficiency Ratios | |||||
| Receivables Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Payables Turnover | 1.53 | 0.00 | 0.00 | 0.00 | 0.00 |
| Inventory Turnover | 11.92 | 0.00 | 0.00 | 0.00 | 0.00 |
| Fixed Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Asset Turnover | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Working Capital Turnover Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Conversion Cycle | -208.15 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Sales Outstanding | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Inventory Outstanding | 30.62 | 0.00 | 0.00 | 0.00 | 0.00 |
| Days of Payables Outstanding | 238.77 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Cycle | 30.62 | 0.00 | 0.00 | 0.00 | 0.00 |
| Cash Flow Ratios | |||||
| Operating Cash Flow Per Share | -0.18 | -0.24 | -0.32 | -0.35 | -0.49 |
| Free Cash Flow Per Share | -0.20 | -0.30 | -0.36 | -0.54 | -0.85 |
| Dividend Paid and CapEx Coverage Ratio | -6.65 | -4.48 | -7.26 | -1.87 | -1.41 |
| Capital Expenditure Coverage Ratio | -6.65 | -4.48 | -7.26 | -1.87 | -1.41 |
| Operating Cash Flow Coverage Ratio | -0.22 | -0.33 | -0.21 | -1.21 | -2.29 |
| Operating Cash Flow to Sales Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow Yield | -7.75% | -13.84% | -8.68% | -13.19% | -6.18% |
| Valuation Ratios | |||||
| Price-to-Earnings (P/E) Ratio | -6.27 | -5.95 | -6.41 | -6.61 | -19.92 |
| Price-to-Sales (P/S) Ratio | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Price-to-Book (P/B) Ratio | -103.70 | -83.60 | 12.35 | 4.14 | 8.58 |
| Price-to-Free Cash Flow (P/FCF) Ratio | -12.91 | -7.23 | -11.52 | -7.58 | -16.19 |
| Price-to-Operating Cash Flow Ratio | -14.85 | -8.84 | -13.11 | -11.63 | -27.71 |
| Price-to-Earnings Growth (PEG) Ratio | -0.38 | 0.13 | -1.32 | 0.65 | 0.66 |
| Enterprise Value Multiple | -10.84 | -9.75 | -16.09 | -9.50 | -21.01 |
| Enterprise Value | 1.83B | 1.45B | 2.88B | 2.20B | 6.81B |
| EV to EBITDA | -10.84 | -9.75 | -16.09 | -9.50 | -21.01 |
| EV to Sales | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EV to Free Cash Flow | -16.36 | -9.42 | -15.45 | -7.91 | -15.63 |
| EV to Operating Cash Flow | -18.82 | -11.53 | -17.58 | -12.13 | -26.76 |
| Tangible Book Value Per Share | 0.03 | -0.07 | 0.25 | 0.90 | 1.57 |
| Shareholders’ Equity Per Share | -0.03 | -0.03 | 0.34 | 0.99 | 1.60 |
| Tax and Other Ratios | |||||
| Effective Tax Rate | 0.00 | -0.00 | 0.00 | -0.10 | -0.06 |
| Revenue Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Net Income Per Share | -0.42 | -0.36 | -0.65 | -0.62 | -0.69 |
| Tax Burden | 1.00 | 1.00 | 1.00 | 0.99 | 1.00 |
| Interest Burden | 1.03 | 0.93 | 1.45 | 1.17 | 1.03 |
| Research & Development to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Stock-Based Compensation to Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Income Quality | 0.42 | 0.67 | 0.49 | 0.56 | 0.72 |
Currency in CNY
